Summary by Futu AI
On March 26, 2024, bluebird bio, Inc. disclosed its financial results for the fourth quarter and the full year ended December 31, 2023, and provided updates on its operational progress and guidance for 2024. The company reported a full year 2023 revenue of $29.5 million, with $7.8 million generated in the fourth quarter. bluebird bio also announced a $175 million term loan facility with Hercules Capital, which is expected to extend the company's cash runway through Q1 2026. The company has seen 9 patient starts in 2024 for its gene therapies ZYNTEGLO and SKYSONA, and anticipates 85 to 105 patient starts across its portfolio in 2024. A government outcomes-based agreement for sickle cell disease was signed with Michigan Medicaid, and 62 qualified treatment centers have been activated. However, bluebird bio also announced that it will...Show More